SEC Filings

SEC Filings
Home / SEC Filings

SEC Filings

10-Q
PROTALIX BIOTHERAPEUTICS, INC. filed this Form 10-Q on 05/10/2017
Entire Document
 

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

PROTALIX BIOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)
(Unaudited)

 

   March 31, 2017   December 31, 2016 
         
ASSETS          
           
CURRENT ASSETS:          
Cash and cash equivalents  $48,017   $63,281 
Accounts receivable – Trade   2,737    693 
Other assets   3,484    2,321 
Inventories   7,100    5,245 
Assets of discontinued operation   205    327 
Total current assets   61,543    71,867 
           
FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT   1,837    1,677 
PROPERTY AND EQUIPMENT, NET   8,472    8,703 
Total assets  $71,852   $82,247 
           
LIABILITIES NET OF CAPITAL DEFICIENCY          
           
CURRENT LIABILITIES:          
           
Accounts payable and accruals:          
Trade  $5,999   $4,007 
Other   12,365    7,496 
Convertible notes        53,872 
Deferred revenues   1,925    837 
Total current liabilities   20,289    66,212 
           
LONG TERM LIABILITIES:          
           
Convertible notes   113,204    19,343 
Liability for employee rights upon retirement   2,528    2,348 
Promissory note   4,301    4,301 
Total long term liabilities   120,033    25,992 
Total liabilities   140,322    92,204 
           
COMMITMENTS          
           
CAPITAL DEFICIENCY   (68,470)   (9,957)
Total liabilities net of capital deficiency  $71,852   $82,247 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

 1